The Truth About Big Pharma's Insulin Prices



FIERCE

What Spurred Lilly, Novo and Sanofi to slash Insulin Prices?

"These pricing moves will likely benefit manufacturers in the long run"¹

"Lilly's cuts are expected to save the company \$430 million in additional rebates and boost earnings by \$85 million."

Los Angeles Times

Eli Lilly is Slashing Insulin Prices, but Hold Your Applause Column by Michael Hiltzik

"The truth is that Lilly's price cuts won't cost it a thin dime in profits; it may even collect higher profits...Lilly's price cuts will produce about \$517 million in gains."

What does it cost to produce one vial of insulin?

The Astonishing Rise of Insulin Prices Over Time

1921		1982	U	2005		2012		2023
University of Toronto sold		\$14		\$60		~\$132		Eli Lilly
insulin patent	1972	per vial (introduction of	1996	per vial •	2010	per vial	2017	Announces
to Eli Lilly for <mark>\$1</mark>	\$9	human insulin)	\$33		\$110		\$275	70% price cut
tor 🤉 I	per vial		per vial		per vial		per vial	on its insulin
			:					products
					:		:	This will decrease the
	•	•	•		:		:	price of Humalog from
•	•	•	•	•	•	•	•	\$274.70 to \$66.40 by
:		•	:	•		•		the end of 2023
:		•	•	•	:	•	•	(still 2/3 higher than it
•	•	•	•	•	•	•	•	should be accounting
•	:	•	•	•	:	•	•	for inflation) ⁴
:		•	•	•		•	•	•
•	:	:	•	:	:	:		
•	•	•	•	•	•	•	•	•

¹ Dafny, Leemore, Ph.D, analysis in the New England Journal of Medicine

² University of Florida

³ Hirsch, Irl, Insulin in America: A Right or a Privilege? American Diabetes Association, Diabetes Spectrum

⁴LA Times: Column by Michael Hiltzik: Eli Lilly is Slashing Insulin Prices, but Hold Your Applause

May 2023

on Big Pharma-backed SB 90

Big Pharma has a track record of raising insulin prices and there is no guarantee they will not decide to raise insulin prices again in the future. Big Pharma-backed co-pay cap legislation like Senate Bill 90 could

lead to higher health care costs for all Californians by allowing big pharma to raise prices at will, without accountability.

Why are Co-pay Caps a Bad Idea?

Artificially placing a cap on co-pays allows Big Pharma to continue charging whatever price they wish for prescription drugs, which will increase health care premiums for everyone in the long run.

Health plans cover over 92% of the cost of prescription drugs, regardless of their price.

Capping co-pays on Big Pharma's behalf ensures drug companies will have a blank check waiting for them should they wish to raise insulin prices again at any time in the future.

SB 90 is an unnecessary bill that places a cap

On co-pays while Big Pharma's insulin prices remain two-thirds higher than they should be, even with their price reduction. And to add insult to injury, there's no assurance that they won't raise insulin prices again in the future, just as they did in 1921, 1972, 1982, 1996, 2005, 2010, 2012, and 2017. Not only that, SB 90 will actually provide Big Pharma with a consumer-signed blank check they can use when they decide to raise their prices, and the health care premiums of all Californians in the future.

Vote No on Big Pharma-backed SB 90